Business of the House

Debate between Mel Stride and Darren Jones

Thursday 11th July 2019 Commons Chamber

[Darren Jones (Bristol North West) (Lab)]

A number of my constituents transferred from AstraZeneca to Avara Pharmaceuticals when the Avalon Pharmaceuticals site north of Bristol was sold. They did so because they were promised that if the business failed, they would still be entitled to their full AstraZeneca redundancy package. That has not happened and those workers are now being made redundant on statutory pay only, although AstraZeneca still has a legal contract with Avara to enforce that right, which expires in October. I have written to the Department for Business, Energy and Industrial Strategy and received a wholly unsatisfactory answer, and I have applied for an Adjournment debate four weeks in a row without success. Does the Leader of the House agree that the matter deserves ministerial attention, and that that should be given before the summer recess?

[Mel Stride]

Clearly I am not in a position to comment on the specifics of the hon. Gentleman’s experience with BEIS Ministers, but I accept that it is very important that he has appropriate contact with them and a proper opportunity to explain the situation fully and see whether something can be done to help. I have two points to make. First, BEIS questions are on Tuesday 16 July, and I think that would be an excellent matter to raise then—I recommend that he give the Department advance notice of his question, if he intends to raise it in topical questions. Secondly, if he would like to meet me to have a quick discussion about the matter, I would be happy to do so, to see how I could otherwise assist.